

# SAVE THE DATE

The Division of Blood Disorders (DBD) is proud to offer its “Webinar Series on Bleeding and Clotting Disorders.” This new webinar series provides evidence-based information on new research, interventions, and emerging issues of interest in blood disorders, as well as innovative approaches in collaborations and partnerships.

To participate, please log on to view the content and dial in to hear the audio.

Visit: <https://www.livemeeting.com/cc/cdc/join?id=76KHDJ&role=attend>. Enter the meeting ID: **76KHDJ** and click “**join.**” Dial the toll-free number: **1 (866) 692-4541** and enter the participant code: **13565573**

## TOPIC

## Inhibitor Testing: State of the Art

## GUEST PRESENTER



### Connie Miller, PhD

Dr. Miller is a medical geneticist who has directed the Clinical Coagulation Laboratory for the Division of Blood Disorders at the Centers for Disease Control and Prevention for 15 years. Previously she spent more than 20 years in clinical care for people with hemophilia. She is currently Team Leader for the Clinical Research Team in the Laboratory Research Branch. Dr. Miller has not only modified existing tests, but also has developed new testing methods to be used for inhibitor testing in hemophilia monitoring.

## WHEN

## THURSDAY, JUNE 5, 2014

2:00–3:00pm EDT

## WEBINAR DESCRIPTION

The development of an inhibitor is a serious problem and is the number one blood product safety issue for people with hemophilia. Inhibitors are a type of antibody produced by the body's immune system in response to factor concentrate (product used to treat bleeding). By neutralizing the effect of the factor product, inhibitors can prevent normal blood clotting in response to bleeding. Inhibitors cause significant morbidity (illness) and mortality (death) as well as considerable healthcare expense in the hemophilia community.

In this webinar, Dr. Miller will describe the different methods available for inhibitor testing, discuss the CDC experience with monitoring patients for inhibitors in a large research project, and explain the CDC laboratory's role in national inhibitor monitoring.

## LEARNING OBJECTIVES

At the end of this webinar, attendees will be able to:

- ▶ List at least two differences in inhibitor test methods.
- ▶ Discuss who is at risk for developing an inhibitor.
- ▶ Describe what CDC does with blood samples submitted as part of the blood monitoring program called Community Counts!

## WHO SHOULD ATTEND

This webinar is free and open to all who are interested in learning about the current state of the science in inhibitor testing.

For more information about the webinar, please contact Cynthia Sayers at [cay1@cdc.gov](mailto:cay1@cdc.gov) or **404-498-0020**.

National Center on Birth Defects and Developmental Disabilities  
Division of Blood Disorders

